Growth, biochemical composition, innate immunity and histological performance of the juvenile humpback grouper ( Cromileptes altivelis) after treatment with recombinant fish growth hormone.

Humpback grouper take a long time to grow to marketable size. In this study, recombinant Epinephelus lanceolatus growth hormone (rElGH) was applied orally and by intraperitoneal injection to accelerate their growth. Daily application of crude rElGH at a dose of 50 mg kg−1 in commercial diet for 42 days or with injections of 0.2 μg rElGH g−1 total body weight every 2 weeks resulted in significant increases in growth performance, protein and lipid content, plasma glucose, liver glycogen and innate immunity compared to control groups. Relative weight gain from the oral and injection doses above compared to C− (Control negative, only commercial diet without rElGH treatment or chemical substances related to treatment, either for oral or injection route) were 40.25% and 38.77%, respectively. There was no specific histological damage to the kidneys, liver or spleen that was attributable to rElGH administration. These results strongly suggested that the stimulation of growth and immunity following oral and intraperitoneal administration was due to a specific action of rElGH and that recombinant GH is safe for fish consumption. [ABSTRACT FROM AUTHOR]